Serious hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants: an exposed-unexposed cohort study in December 2021 from the COVID-19 surveillance databases in France

Study design

This is a retrospective cohort study carried out by combining the French COVID-19 surveillance databases. The study covers the period from 06/12/2021 to 07/01/2022. During this period, the variants Omicron and Delta circulated in France. The outcome of the study was the occurrence of a serious hospital event associated with COVID-19 (admission to intensive care unit OR admission to critical care unit OR death), among symptomatic persons testing positive for SARS-CoV-2, classified as Delta or Omicron using mutation screening. The cohort had two arms, consisting of Delta and Omicron variant cases respectively. Individual matching was performed on the calendar week of virological diagnosis, to compare contemporary cases, and on age, which is a major risk factor for the occurrence of severe events. In addition to matching, adjustment for four known risk factors (age, sex, vaccination status and presence of comorbidity) and region of residence was performed using Cox proportional-hazards model.

Data sources

To carry out its surveillance missions, Santé publique France receives pseudonymised health data from three information systems placed under the responsibility of the Ministry of Health. These three databases respectively include results of all SARS-CoV-2 tests (RT-PCR and antigen tests, excluding self-tests) performed in the country (SI-DEP), summary data on hospital stays, outcomes and types of wards (SI-VIC) and COVID-19 vaccine status and comorbidities of the whole French population» (VAC-SI). The extraction of data for events that took place from 06/12/2021 was carried out on 11/01/2022. As four days are required for 90% of hospital events to be reported in the SI-VIC database, events after 07/01/2022 were excluded to control for reporting bias. A pseudonym, based on the surname, first name, date of birth, sex of the patients and a hash key was used to merge the three data sources.

Eligibility criteria

Persons older than 18 years on the day of inclusion, sampled for SARS-CoV-2 diagnostic between 06/12/2021 and 02/01/2022 (inclusive) and declared as symptomatic at sampling, with a confirmed SARS-CoV-2 infection and valid RT-PCR mutation screening were included. Exposed persons are those with a strong suspicion of the Omicron variant (see below). Non-exposed persons are those with a strong suspicion of the Delta variant, based on the screening results. Persons with missing data, as well as those not found in the VAC-SI database or with an inconsistent vaccination status were excluded.

Variables

Participants

The numbers at different stages of the inclusion process are as follows:

• People over 18 with symptoms, sample taken during the inclusion period and RT-PCR positive with a valid result for mutation screening: 414,527

• Exclusion of 8,956 persons with missing sex or postal code in SIDEP: remaining 405,571

• Exclusion of 64 059 persons not found in VAC-SI: remaining 341 512

• Matching: 74,532 pairs constituted (149,064 persons) and exclusion of unmatched persons

Descriptive data

Numbers in the two arms of the cohort reflected the dynamic of the spread of the Omicron variant in France during December 2021 (Table 1). Few people were included during weeks 49 and 50 because the Omicron variant was then uncommon in France. The vast majority of inclusions took place during weeks 51 and 52. Geographically, the Ile-de-France region accounted for 23% of those infected with the Omicron variant and only 6.7% of those infected with the Delta variant; this region has been indeed the first to be largely affected by the Omicron variant. Conversely, the Delta variant was still very frequent in the Provence-Alpes-Côte-D’Azur and Occitanie regions during the four weeks of the study. The gender distribution was very similar between the two arms, although the difference was statistically significant. The distribution of vaccination status was very different between the two arms of the cohort. The percentage of unvaccinated individuals was more than twice as high in the DELTA arm as in the OMICRON arm (36% vs. 17%). Overall, 84% of first injections were with Pfizer/BioNTech vaccine, 9.5% with Moderna, 5.0% with AstraZeneca and 1.2% with Janssen; there was no difference between the two arms. The distribution of comorbidities was statistically different between the two arms, with slightly more comorbidities in the DELTA arm, but this difference was small (Table 2). The percentage of people who have had a booster shot increased very strongly with age (Table 3). This reflects the phased roll-out of vaccination in France since the beginning of 2021.

Follow-up and outcome data

The maximum follow-up time was 32 days, however, very few people were followed up over this period (Figure 1). This was expected, as few people were included in the first two weeks of the study. However, 81% of people were followed up for at least 10 days. A total of 497 serious hospital events were observed during the follow-up period (Table 4). The number of serious hospital events was significantly higher in the DELTA arm (447) than in the OMICRON arm (50). The most frequent event was admission to the intensive care unit. The sum of the numbers of ICU admissions, CCU admissions and deaths is higher than the number of serious events, as the same person may be involved in more than one type of event. In the DELTA arm of the cohort, 92% of serious events were observed within 14 days of positive sampling, and 97% within 21 days. In the OMICRON arm, 84% of events occurred within 14 days and 100% within 20 days (Figure 1).

• Download figure
• Open in new tab

Evolution since the virological diagnosis of the cumulative probability of a serious hospital event among cases infected by the Omicron or Delta variant of the SARS-CoV-2, December 2021-January 2022, France, (n= 149,064)

Univariate analysis

The crude hazard ratio for of a serious hospital event was statistically different between the two arms of the cohort for all covariate modalities, except for the region (statistically significant for 4 of the 13 regions, Table 5). Table 6 gives the absolute number of serious events observed per 100,000 people within 21 days of positive sampling, for each covariate value. The number of serious events was greater for those with a booster than for those with a complete primary vaccination. This counter-intuitive observation is analysed in the multivariate model.

Multivariate analysis

As the univariate analysis showed that all the variables were related to the occurrence of a serious event (p<0.2), they were all included in the multivariate analyses. Models were adjusted for region of residence, but this variable is not presented in the tables for simplicity. The overall model (not shown) showed a risk reduction in the Omicron arm (adjusted Hazard Ratio = 0.10), but also an interaction between variant and age, which means that the hazard ratio between Delta and Omicron is not identical in all age groups. To simplify the interpretation of the results, two sub-models are presented: one for people aged 18-79 and the other for people aged 80 and over (Table 7). No interaction was found between age and vaccination in the 18-79 year old model. People aged 18-79 years with symptomatic infection by the Omicron variant had a 7.7 times lower risk (5.6-11.1) of having a serious hospital event than those with symptomatic infection by Delta [HR=0.13; CI95 0.09-0.18]. In people aged 80 years and over, the difference in risk between the two variants was smaller: Omicron cases had a 3.3-fold lower risk (5.6 to 11.1) than Delta cases [HR=0.30; CI95 0.17-0.54].

The risk of a serious event increased sharply with age: the absolute risk for the reference population (unvaccinated women without comorbidity, infected with Delta) was 140/100,000 for 18-39 year olds [95% CI 81-199], 913 [603-1,214] for 40-64 yo, 4,844 [2,999-6,427] for 64-79 yo, and 58,419 [6,160-66,872] for ⩾ 80 yo. The models also highlighted the levels of risk associated with other covariates: the risk was almost twice as high for men as for women, with no major difference between those aged 18 to 79 and those aged 80 and over; the risk was reduced in vaccinated people. Between the ages of 18 and 79, the risk was divided by 6.7 for those who had been vaccinated, whether or not they had received a booster [HR=0.15]. In people over 80 years of age, the risk was divided by 4.3 with a booster and 2.2 with a primary vaccination [HR=0.23 and 0.46] ; the risk was increased in case of co-morbidity in 18-79 year olds (3.7 times for very-high-risk comorbidity and 2.8 times for medium-risk comorbidities). In the over 80s the risk associated with comorbidities was not statistically significant.

Key results

Our national cohort study confirms the lower severity of Omicron infections compared to Delta infections in adults, by quantifying the risk of a serious hospital event i.e. the admission in intensive care unit (ICU), critical care unit (CCU) or death during hospitalization. We defined this outcome as death may occur in patients not admitted to ICU wards, such as frail elderly patients. [9]. People aged 18 to 79 years had a 7.7 times lower risk of severe outcome when infected with the Omicron variant (HR=0.13). However the risk ratio was only of 3.3 in the 80 year-olds and older (HR=0.30).

Substantial decrease in severity of Omicron cases compared with Delta cases has been considered in different studies. In South Africa, after controlling for factors associated with hospitalization, individuals with S Gene Target Failure (SGTF), used as a proxy for Omicron infection, had lower odds of being admitted to hospital compared to non-SGTF infections, used as a proxy of Delta infection (0.2, 95%CI 0.1-0.3). However, the Delta and Omicron cohorts in this study were not contemporaneous and the Omicron cohort had more acquired immunity which might have lessened the estimated severity of Omicron. [10] Studies with contemporary cohorts have since been conducted in Canada [11], the USA [12], UK [13] and Norway [14]. Our results align with findings in Ontario, Canada; this matched cohort study described a reduction of 83% (HR: 0.17; CI95 0.08-0.37) in admission to intensive care unit or death for Omicron cases when compared to Delta cases. In the United States (California), the hazard ratios between Delta and Omicron cases, after a positive outpatient test, were 0.26 (CI95 0.10-0.73) for admission to intensive care and 0.09 (CI95 0.01-0.75) for death. In the UK, the reduction in the risk of hospitalisation during a 4-day follow-up was 65%. In Norway, Omicron was associated with an overall 73% reduced risk of hospitalisation (HR = 0.27 CI95 0.20–0.36) compared with Delta.

The study also quantified the protection provided by vaccination. In Norway, an interaction between the variant and vaccination status was detected in the subgroup of people with primary vaccination completed 7-179 days ago, suggesting a weaker effectiveness of the vaccine for Omicron cases than for Delta cases (66% and 93%, respectively) [14]. In our study we did not find evidence of such an interaction although the size of our cohort is larger; however, our study focused on severe hospital events whereas the Norwegian study considered all hospital admissions, suggesting that the effectiveness of vaccination against severe forms of COVID-19 is equivalent for both variants. Nevertheless, as the individuals were symptomatic at inclusion in the cohort, our results did not take into account either the possible differential capacity of the two variants to cause symptomatic infection, or the capacity of the vaccines to prevent symptomatic infection. The fact that we observed 44% of unvaccinated individuals in the Delta arm and only 20% in the Omicron arm seems to support a partial vaccine escape for the prevention of symptomatic infection by the Omicron variant as reported in other studies. Nevertheless, vaccination remained effective in preventing serious hospital events. Further studies are needed to better understand the differences between Delta and Omicron ahead of symptomatic infection. Buchan and al also showed that two doses of COVID-19 vaccines were unlikely to protect against infection by Omicron (irrespective of symptoms or severity) and vaccine effectiveness against this variant was only 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose in a population with a high proportion of immunosuppressed patients [15]. The duration of this protection and effectiveness against severe disease are uncertain. In contrast, after 2 doses of COVID-19 vaccine, vaccine effectiveness against Delta infection declined steadily over time but recovered to 93% (95%CI, 92-94%) ≥7 days after receiving an mRNA vaccine for the third dose [15].

The risk of ICU admission, CCU admission or death was almost three times higher for patients with comorbidities than for those without, with a tendency to be higher for “very high risk” comorbidities. The absence of interaction showed that this excess risk was present for both variants. The higher risk of developing severe COVID-19 infection in patients with underlying medical comorbidities has been widely described and may lead to up to a six-fold increase in hospitalisation [16].

The risk of ICU admission or death was almost two times higher among males compared to females. The absence of interaction evidenced in our study is in favour of this excess risk existing for both variants. The increased risk of developing severe COVID-19 infection and increased mortality due to COVID-19 for male has already been described [16-18].

Strengths of the study

Studies comparing consecutive waves of the epidemic may lead to confounding biases as the decrease in disease severity in the Omicron cohort could reflect an increase in the vaccination rate, a change in the characteristics of the infected population or a change in hospital care over time. In our study, to control such a bias, each Omicron case was matched on age and date of onset to a Delta case. In addition, a multivariate analysis was used to adjust the hazard ratio of severe events between Delta and Omicron variants infections on gender, age, vaccination status and comorbidities, which are known risk factors for severe forms of COVID-19. Cox proportional hazards models allowed for different follow-up times.

The time required to integrate 90% of the data into the SI-VIC database is estimated to be 4 days. This was taken into account by stopping the follow-up four days before the data extraction. The duration of follow-up was ≤ 33 days and 81% of cases were followed for at least 10 days. This duration was longer than in a United Kingdom cohort followed during the very first days of the Omicron wave [13]. This appears to be long enough, as 92% of serious events following symptomatic Delta infection and 84% following symptomatic Omicron infection occurred within 14 days of virological diagnosis. Infections diagnosed from the day after hospitalisation were not included, preventing the risk of nosocomial infections being included in the study.

All cases included in this study were screened by RT-PCR in order to identify a set of target mutations. We designed an algorithm to classify cases in suspected Delta cases, suspected Omicron cases and other variant/inconclusive. Using cases for which a sequencing result was also available, we found a specificity of our algorithm of 99.1% for Delta and 92.9% for Omicron. PCR screening did not allow to segregate between the two main Omicron sub-lineages, BA.1 and BA.2, but as of 15 January 2022, BA.2 was very rarely detected in France. It is also important to note that the algorithm used in this study was designed according to the variants circulating in France during the study period, and might not be adaptable to other timeframes

Limitations

In this study, vaccination status was characterised only by discriminating between the non-vaccinated, the primo-vaccinated and the booster-vaccinated. Studies with more power are needed to assess other parameters, such as the time between the last injection and exposure or the type of vaccine. According to a study, the injection of a booster dose reduces the risk of hospitalization of Omicron cases between 70 and 88% [19, 20] and severe forms by 98% [21]. Although, information on a known previous infection is used to determine the required number of injections (e.g. one single dose for primary vaccination in case of known previous infection), it was not possible to take into account this information in our model, but it would be useful to include it in future studies.

Another limitation is the imperfect merge, by pseudonym, between the three databases: 16% of the persons fulfilling the inclusion criteria in SI-DEP were excluded because they were not found in VAC-SI. It is also possible that not all hospital events were found in SI-VIC. However, there is no reason why this loss of information should differ between the two arms of the cohort and therefore affect the risk ratios.